New pastille could change head and neck cancer treatment

NCT ID NCT07667296

Not yet recruiting Disease control Sponsor: Aveta Biomics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This large Phase 3 trial is testing a new drug called APG-157, given as a pastille that dissolves in the mouth, for people with advanced head and neck cancer. The study will see if adding APG-157 before and after standard treatments (surgery or chemoradiation) helps keep the cancer from coming back. About 826 participants will be enrolled, but the trial has not started recruiting yet.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: APG-157 (a pastille that dissolves in the mouth)
What this could lead to: If it works, this could offer a new treatment option for people with advanced head and neck cancer, potentially improving how long they live without the cancer coming back.
What could go wrong: This is a large, late-stage trial, but it's not yet recruiting. APG-157 is still experimental, and it's unknown if it will be more effective than current standard treatments. Side effects are also not yet fully understood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK (HNSCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma Mouth Neoplasms oral cavity carcinoma oral cavity squamous cell carcinoma oropharynx squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK (HNSCC) HEAD AND NECK CANCER ORAL CAVITY ORAL CAVITY CARCINOMA ORAL CAVITY SQUAMOUS CELL CARCINOMA OROPHARYNGEAL OROPHARYNX SQUAMOUS CELL CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.